The FDA has approved Novartis’ Afinitor DISPERZ® (everolimus tablets for oral suspension), for the adjunctive treatment of adult and pediatric patients aged two years and older with tuberous sclerosis complex (TSC)-associated partial-onset seizures.    Afinitor DISPERZ is now the first approved pharmacologic therapy in the US specifically indicated for the treatment of this condition. TSC is a rare genetic disorder affecting up to one million people worldwide. Approximately 85% of indivi...